Our results demonstrated that Oligonol may prevent hepatic steatosis by regulating AMPK-mTOR and STAT3-SOCS3 signaling pathways, and that these pathways are good therapeutic targets for treating hepatic dysfunction. This evidence concerns the gene MTOR and fatty liver disease.